|
 The data, yet to be published in a peer-reviewed medical journal,
shows that the companies' treatment, sotrovimab, is effective
against all 37 identified mutations to date in the spike protein,
GSK said in a statement.
Last week, another pre-clinical data showed that the drug had worked
against key mutations of the Omicron variant. Sotrovimab is designed
to latch on to the spike protein on the surface of the coronavirus,
but Omicron has been found to have an unusually high number of
mutations on that protein.
"These pre-clinical data demonstrate the potential for our
monoclonal antibody to be effective against the latest variant,
Omicron, plus all other variants of concern defined to date by the
WHO," GSK Chief Scientific Officer Hal Barron said.
[to top of second column] |
 GSK and Vir have been
engineering so-called pseudoviruses that feature
major coronavirus mutations across all
suspicious variants that have emerged so far,
and have run lab tests on their vulnerability to
sotrovimab treatment.
(Reporting by Pushkala Aripaka in Bengaluru;
Editing by Sherry Jacob-Phillips)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
